25

5

10

What is claimed is:

- Isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule
 encoding a patched-2 polypeptide comprising the sequence of amino acids 1 to about 1203 of Fig. 1 (SEQ ID
 NO:2), and encoding a polypeptide having patched-2 biological activity.
- An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA
 molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209778
 designation;, or (b) the complement of the DNA molecule of (a).
 - The isolated nucleic acid of Claim 5 comprising human patched-2 encoding sequence of the cDNA in ATCC deposit No. 209778 designation:, or a sequence which hybridizes thereto under stringent conditions.
 - 4. A vector comprising the nucleic acid of Claim 1.
 - The vector of Claim 4 operably linked to control sequences recognized by a host cell transformed with the vector.
 - A host cell transformed with the vector of Claim 4.
 - 7. The host cell of Claim 6 which is mammalian.
 - The host cell of Claim 7 wherein said cell is a CHO cell.
 - 9. The host cell of Claim 6 which is prokaryotic.
 - The host cell of Claim 9 wherein said cell is an E. coli.
- 30 11. The host cell of Claim 7 wherein said cell is a yeast cell.
 - The host cell of Claim 11 which is Saccharomyces cerevisiae.
- A process for producing patched-2 polypeptides comprising culturing the host cell of Claim 9 under
 conditions suitable for expression of vertebrate patched-2 and recovering patched-2 from the cell culture.

25

5

- Isolated native sequence human patched-2 polypeptide comprising amino acid residues 1 to 1203 of
 I (SEO ID NO:2).
- Isolated native sequence human patched-2 polypeptide encoded by the nucleotide deposited under accession number ATCC 209778 Designation having patched-2 biological activity.
 - 16. A chimeric molecule comprising vertebrate patched-2 polypeptide patched-2 to a heterologous amino acid sequence.
- 10 17. The chimeric molecule of Claim 16 wherein said heterologous amino acid sequence is an epitope tag sequence.
 - 18. The chimeric molecule of Claim 17 wherein said heterologous amino acid sequence is a constant region of an immunoglobulin.
 - An antagonist of patched-2 which blocks, prevents, inhibits and/or neutralizes the Dhh function in the Dhh signaling pathway.
 - The antagonist of Claim 19 which is a small bioorganic molecule.
 - 21. The antagonist of Claim 19 which is an antisense nucleotide.
 - An agonist of patched-2 with stimulates or enhances the normal functioning of patched-2 in the Dhh signaling pathway.
 - 23. The agonist of Claim 22 which prevents Smo (SEQ ID NO:17) inactivation of Ptch-2 (SEQ ID NO:2).
 - The agonist of Claim 22 which is a small bioorganic molecule.
- 30 25. The agonist of Claim 24 which is a small bioorganic molecule.
 - A method of screening for antagonists or agonists of patched-2 biological activity comprising:
 - (a) exposing patched-2 expressing target cells in culture to a candidate compound and Dhh; and
 - (b) analyzing cells for binding of Dhh to patched-2; or
- 35 (c) scoring phenotypic or functional changes in the treated cells; and comparing the results to control cells which were not exposed to the candidate compound.

- 27. A method of screening for antagonist or agonist molecule of patched-2 biological activity comprising:
 - exposing a patched-2 ligand and a compound having patched-2 biological activity to a candidate antagonist or agonist; and
- 5 (b) analyzing the substrate for binding of the ligand to the compound; and comparing the results to control reactions which were not exposed to the candidate molecule.
 - 28. A method of diagnosing to determine whether a particular disorder is modulated by *Dhh* signaling, comprising:
- (a) culturing test cells or tissues;
 - (b) administering a compound which can inhibit patched-2 modulated Dhh signaling; and
 - (c) analyzing the level of Dhh binding to patched-2 or Dhh mediated phenotypic effects in the test cells.